Abuse Potential of Samidorphan: A Phase I, Oxycodone-, Pentazocine-, Naltrexone-, and Placebo-Controlled Study-Reference-Cited by-同舟云学术

Abuse Potential of Samidorphan: A Phase I, Oxycodone-, Pentazocine-, Naltrexone-, and Placebo-Controlled Study

Published:2018-11-26 Issue:2 Volume:59 Page:218-228
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Pathak Sanjeev¹^ORCID,Vince Bradley²,Kelsh Debra²,Setnik Beatrice³⁴,Nangia Narinder¹,DiPetrillo Lauren¹,Puhl Matthew D.¹,Sun Lei¹,Stanford Arielle D.¹,Ehrich Elliot¹

Affiliation:

1. Alkermes, Inc.; Waltham MA USA

2. Vince & Associates Clinical Research, Altasciences; Overland Park KS USA

3. Syneos Health; Raleigh NC USA

4. University of Toronto; Department of Pharmacology & Toxicology; Toronto ON Canada

Funder

Alkermes, Inc.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.1343/fullpdf

Reference16 articles.

1. Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone;Wentland;Bioorg Med Chem Lett,2005

2. Syntheses of novel high affinity ligands for opioid receptors;Wentland;Bioorg Med Chem Lett,2009

3. vitro and in vivo characterization of novel opioid antagonists;Todtenkopf;Alcohol Clin Exp Res,2008

4. Samidorphan attenuates drug-induced increases in extracellular dopamine concentrations and drug self-administration in rats;Cunningham;Eur Neuropsychopharmacol,2014

5. In vitro pharmacological characterization of buprenorphine, samidorphan, and combinations being developed as an adjunctive treatment for major depressive disorder;Bidlack;J Pharmacol Exp Ther,2018

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users;Translational Psychiatry;2023-06-07

2. Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review;Frontiers in Pharmacology;2022-10-03

3. Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review;Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy;2022-09

4. Olanzapine/Samidorphan: A New Option for the Treatment of Adults With Schizophrenia or Bipolar I Disorder;Journal of Pharmacy Technology;2022-07-29

5. Comparative study of dezocine, pentazocine and tapentadol on antinociception and physical dependence;Life Sciences;2021-11